- Home
- ANL vs RLMD Comparison
ANL vs RLMD Comparison
Compare ANL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- RLMD
- Stock Information
- Founded
- ANL 2004
- RLMD 2004
- Country
- ANL Cayman Islands
- RLMD United States
- Employees
- ANL N/A
- RLMD N/A
- Industry
- ANL
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- RLMD Health Care
- Exchange
- ANL Nasdaq
- RLMD Nasdaq
- Market Cap
- ANL 61.8M
- RLMD 52.8M
- IPO Year
- ANL 2023
- RLMD N/A
- Fundamental
- Price
- ANL $1.79
- RLMD $1.52
- Analyst Decision
- ANL Hold
- RLMD Buy
- Analyst Count
- ANL 1
- RLMD 3
- Target Price
- ANL N/A
- RLMD $5.00
- AVG Volume (30 Days)
- ANL 9.3K
- RLMD 1.7M
- Earning Date
- ANL 09-26-2025
- RLMD 11-06-2025
- Dividend Yield
- ANL N/A
- RLMD N/A
- EPS Growth
- ANL N/A
- RLMD N/A
- EPS
- ANL N/A
- RLMD N/A
- Revenue
- ANL N/A
- RLMD N/A
- Revenue This Year
- ANL N/A
- RLMD N/A
- Revenue Next Year
- ANL N/A
- RLMD N/A
- P/E Ratio
- ANL N/A
- RLMD N/A
- Revenue Growth
- ANL N/A
- RLMD N/A
- 52 Week Low
- ANL $1.10
- RLMD $0.24
- 52 Week High
- ANL $3.89
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- ANL 60.57
- RLMD 66.57
- Support Level
- ANL $1.65
- RLMD $1.44
- Resistance Level
- ANL $1.88
- RLMD $1.72
- Average True Range (ATR)
- ANL 0.10
- RLMD 0.28
- MACD
- ANL 0.00
- RLMD 0.03
- Stochastic Oscillator
- ANL 58.02
- RLMD 68.65
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.